Heron Therapeutics, Inc. /DE/ splits its revenue into 4 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was CINVANTI at $21.8 million, 58% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
151
|
38
|
35
|
41
|
38
|
37
|
39
|
41
|
33
|
| CINVANTI |
89
-10.3%
share 59.0%
|
22
-9.7%
share 57.9%
|
21
-20.2%
share 59.2%
|
23
-14.7%
share 56.5%
|
24
+5.7%
share 62.7%
|
24
share 64.9%
|
26
share 66.2%
|
27
share 65.9%
|
23
share 69.1%
|
| ZYNRELEF |
43
+39.4%
share 28.5%
|
11
+35.0%
share 29.4%
|
10
+27.3%
share 29.5%
|
13
+48.2%
share 30.9%
|
9
+49.1%
share 24.4%
|
8
share 22.0%
|
8
share 20.7%
|
8
share 20.7%
|
6
share 19.0%
|
| Aponvie |
15
+86.2%
share 9.6%
|
4
+73.6%
share 11.4%
|
3
+50.2%
share 9.8%
|
4
+97.5%
share 9.4%
|
3
+166.1%
share 7.9%
|
2
share 6.6%
|
2
share 5.8%
|
2
share 4.7%
|
1
share 3.5%
|
| SUSTOL |
4
-62.5%
share 2.9%
|
1
-77.5%
share 1.4%
|
1
-80.9%
share 1.6%
|
1
-62.3%
share 3.3%
|
2
-30.8%
share 5.0%
|
2
share 6.5%
|
3
share 7.3%
|
4
share 8.6%
|
3
share 8.4%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- HRTX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 818033
- Former names
- AP PHARMA INC /DE/ (until Jan 7, 2014); ADVANCED POLYMER SYSTEMS INC /DE/ (until Apr 6, 2001)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.